Stocks
Schott Pharma Stock Surges on JPMorgan Overweight Rating and Fresh 52-Week High
Schott Pharma's stock price surged on September 16, 2026, following an Overweight rating from JPMorgan and a fresh 52-week high of EUR 23.85 reached on September 15, 2026.
The bank set a price target of EUR 27.10 for the company, citing its role as a specialist in storage and delivery solutions for injectable medicines and expected earnings growth potential of around 14 percent per year through 2029.
Intraday trading saw Schott Pharma shares rise by up to roughly 4 percent as investors digested the new Overweight call from JPMorgan, which was part of a broadly constructive analyst stance surrounding the stock.